January 30, 2023
1 minute read
Source/Disclosure
Disclosure:
Bosch reports that it receives personal fees from Bayer AG event arbitrations outside of the submitted work. See research for relevant financial disclosures of all other authors.
Antihypertensive drugs and statin-containing tablets with or without aspirin were associated with less functional decline in people over the age of 65, but not with less cognitive decline, the researchers said. reported. JAMA Neurology.
“Vascular risk factors are associated with cognitive decline, but studies addressing individual risk factors have not demonstrated an effect of risk factor management on cognitive maintenance.” Dr. Jacqueline J. Boschresearchers at McMaster University and Hamilton Health Sciences in Ontario, Canada, wrote:
Polypills, with or without aspirin, were associated with reduced functional decline in people aged 65 and older, but not with reduced cognitive decline. Source: Adobe Stock
Bosch et al. conducted a randomized clinical trial in adults aged 65 and older showing that a polypill containing 100 mg atenolol, 25 mg hydrochlorothiazide, 10 mg ramipril, and 40 mg simvastatin reduced cognitive and functional decline. I decided if I could. Cardiovascular disease, but moderate risk.
Participants were recruited from hospitals and community-based centers in eight countries, and 2,098 people aged 65 and older at intermediate risk for cardiovascular disease were included in the study. Cognitive and functional assessments were performed at baseline, 2 years, and 5 years at the end of the study.
The researchers found that of all participants (mean age 70.1 years, 60% female), 86% (n = 1,796) had hypertension and 32% (n = 680) had impaired fasting blood glucose levels. discovered. Mean baseline systolic blood pressure was 146.1 mm Hg and mean low-density lipoprotein cholesterol was 124.3 mg/dL.
Patients in the polypill group had a mean blood pressure reduction of 5.7 mmHg and a mean cholesterol reduction of 24 mg/dL. The same group had reduced functional decline during follow-up compared to the placebo-treated group (mean standard assessment of global daily activities). [SAGEA] score, 0.06 vs. 0.15), also decreased in patients receiving polypills and aspirin compared to those receiving placebo (mean SAGEA score, 0.01 vs. 0.14).
The authors said that polypills, with or without aspirin, were ineffective in reducing the risk of cognitive decline or dementia.
“Our findings highlight the importance of extending cardiovascular testing results to routinely include measures of functional status,” Bosch and colleagues wrote. “His SAGEA scale used in this study was specifically developed to measure changes in cognitive, mechanical and basic function that are most susceptible to deterioration due to vascular disease.”
